Merck, Moderna in personalized cancer vaccine deal

Moderna Therapeutics Inc. (Cambridge, Mass.) and Merck & Co. Inc.(NYSE:MRK) partnered to develop and commercialize mRNA-based cancer vaccines that encode patient-specific neoantigens. Merck

Read the full 236 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE